All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Circulating, extracellular ribonucleic acid is a potent activator of type I interferon which plays a central pathogenic role in systemic lupus erythematosus (SLE). RSLV-132, a catalytically active human RNase I fused with human immunoglobulin G1 fragment crystallizable region, is designed to degrade extracellular RNA, and alleviate chronic inflammation linked with SLE.
Here, we summarize an article by Burge et al.1 published in Lupus Science & Medicine, evaluating the efficacy and safety of RSLV-132 in patients with SLE in a phase IIa trial.
Figure 1. Change from baseline in A CLASI, SLEDAI-2K, PGA, and B BILAG*
BILAG, British Isles Lupus Assessment Group; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.
*Data from Burge, et al.1
Figure 2. Composite analysis endpoint*
BICLA, British Isles Lupus Assessment Group-based Composite Lupus Assessment; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SRI, SLE Responder Index 4.
*Adapted from Burge, et al.1
Key learnings |
|
Subscribe to get the best content related to lupus delivered to your inbox